First-line therapy in relapsing remitting multiple sclerosis

D Biotti; J Ciron

doi:10.1016/j.neurol.2018.03.012

First-line therapy in relapsing remitting multiple sclerosis

Rev Neurol (Paris). 2018 Jun;174(6):419-428. doi: 10.1016/j.neurol.2018.03.012. Epub 2018 Apr 25.

Authors

D Biotti¹, J Ciron²

Affiliations

¹ Pole des neurosciences, B4 Neurology unit, CHU de Purpan, Toulouse, France. Electronic address: biotti.d@chu-toulouse.fr.
² Pole des neurosciences, B4 Neurology unit, CHU de Purpan, Toulouse, France.

PMID: 29703445
DOI: 10.1016/j.neurol.2018.03.012

Abstract

Today, first-line treatments for multiple sclerosis include injectable immunomodulators - some of which have been on the market for nearly 25 years - as well as teriflunomide and dimethyl fumarate, which are more recent, but have opened the way for oral treatments. These drugs are considered similar in effectiveness, and their safety and side-effect profiles are generally reassuring. These treatments have been associated with a reduction in radiological and clinical disease activity, and a positive effect on patient quality of life, especially when introduced early in the disease process. This article will discuss data on first-line treatments currently available in France, their effectiveness and safety, and their place in pediatric patients and in woman who plan to become pregnant.

Keywords: Fumarates; Glatiramer acetate; Interferon; Multiple sclerosis; Teriflunomide; Treatment.

Publication types

Review

MeSH terms

Drug Administration Routes
Drug Administration Schedule
France
Humans
Immunologic Factors / administration & dosage*
Immunologic Factors / adverse effects
Immunosuppressive Agents / administration & dosage*
Immunosuppressive Agents / adverse effects
Multiple Sclerosis, Relapsing-Remitting / therapy*
Quality of Life
Treatment Outcome

Substances

Immunologic Factors
Immunosuppressive Agents